ALS Limited (ASX:ALQ), the global testing, inspection and analysis group, operated its Dividend Reinvestment Plan (DRP) for the FY26 final dividend of 23.1 cents per share. The plan carried no discount, and ALS stated that DRP shares would be acquired on market rather than newly issued, with a new issue only as a fallback.

Latest developments

ALS reported a record result for FY26. Revenue rose 10.7% to $3.32 billion, underlying net profit after tax (NPAT) increased 25.8% to $381.2 million, and statutory NPAT increased 24.4% to $318.7 million. Underlying EBIT rose 19.3% to $599.0 million, lifting the underlying EBIT Margin to 18.0%, while free Cash Flow reached $674.1 million.

The board declared a final dividend of 23.1 cents per share, 30% franked, taking the full-year dividend to 42.5 cents, up 10.1%. That represents a Payout Ratio of 57%. Cash conversion from EBITDA was 92%, and Capital Expenditure totalled $263 million, largely growth-related and including the company's hub laboratory programme. Net Leverage was 1.5 times, below the company's 1.7 to 2.3 times target range.

At its annual general meeting, ALS said it was on track to deliver its FY27 outlook and had agreed to lift its stake in its Saudi Arabian joint venture to 60%, subject to regulatory approval. It also announced new executive appointments to lead its Environmental and Minerals businesses.

Key numbers

ALS paid two dividends in respect of FY26: an Interim Dividend of 19.4 cents and a final dividend of 23.1 cents, totalling 42.5 cents per share. The final dividend is 30% franked.

The value of franking credits depends on each investor's tax position. The final dividend was paid after the Record Date set out in the company's dividend notice.

About the company

ALS provides testing, inspection and analytical services to a wide range of industries worldwide. It reports through two divisions. Commodities, which includes minerals testing for the exploration and Mining sector, lifted revenue 18.8% to $1.29 billion in FY26. Life Sciences, covering environmental, food and pharmaceutical testing, grew revenue 6.0% to $2.03 billion.

Malcolm Deane is chief executive officer and managing director. The company's financial year ends on 31 March, so interim results are reported for the six months to September and full-year results for the year to March.

How the DRP works

For the FY26 final dividend, according to the dividend notice lodged with the ASX, ALS's DRP price was set at the volume-weighted average price (VWAP) over the five consecutive trading days following the DRP election date, with no discount applied. Elections closed shortly after the record date, and the pricing period followed immediately.

ALS said DRP shares would be acquired on market through a broker during the pricing period, with new shares issued only as a fallback if purchases were not completed. Where shares are acquired on market, participants receive existing shares and the plan does not add to the share count. The DRP rules and each dividend notice set out the terms that apply, and the board can change the discount or allocation method for each dividend.

Why it matters for income investors

ALS's full-year dividend increased 10.1% in FY26, alongside higher underlying Earnings and free cash flow. The dividend is partially franked, so the franking Credit attached is smaller than for a fully Franked Dividend of the same amount.

The DRP allows participants to reinvest dividends without brokerage. Where DRP shares are acquired on market, the plan does not dilute holders who take cash, and shares allocated under the plan are themselves eligible for later dividends.

What comes next

At its FY26 result, ALS guided to mid to high single-digit organic revenue growth in FY27, with further margin expansion. It expects Minerals organic revenue growth of 13% to 15%, and improved mid-single-digit organic growth in Life Sciences. Hub laboratory upgrades in Sydney and Lima are expected to be commissioned in FY27.

The next interim result, for 1H27, will follow the end of the September half. Other matters of interest include completion of the Saudi joint venture transaction, which remains subject to regulatory approval, the level of minerals exploration activity, and whether Life Sciences growth improves in the second half as management expects. Any future dividend amount, franking level or DRP terms will be set by the board and disclosed in a dividend notice.

Risks and context

Past dividends are not a forecast. Dividends depend on earnings, and the Commodities division is exposed to the mining exploration cycle, which can change sharply. ALS has said Life Sciences growth has been below its target, and investment in new hub laboratories carries execution risk. ALS earns much of its revenue offshore, so currency movements affect reported results.

Reinvested dividends are still assessable income, and each DRP allocation sets a new cost base for Capital Gains Tax purposes, so record-keeping matters. The franking level has changed over recent years and may change again.

Conclusion

ALS Limited (ASX:ALQ) declared a 23.1 cent final dividend, 30% franked, and operated a DRP for that dividend at no discount, with shares to be acquired on market. The company reported record FY26 earnings, lower net leverage and FY27 guidance, while exposure to the minerals cycle, currency movements and partial franking remain relevant context.

Key Insights

ALS Limited (ASX:ALQ) lifted its full-year dividend to 42.5 cents per share in FY26, with the final dividend of 23.1 cents 30% franked, on the back of record underlying earnings, higher free cash flow and net leverage below its target range.

Its DRP operated for the final dividend at no discount, with the price set by a five-day VWAP and shares to be acquired on market, meaning the plan is not expected to add to the share count. FY27 guidance, the Saudi joint venture stake increase and future dividend terms all remain subject to conditions and board decisions.